Outputs (14)

The localization of pre mRNA splicing factor PRPF38B is a novel prognostic biomarker that may predict survival benefit of trastuzumab in patients with breast cancer overexpressing HER2 (2017)
Journal Article
Abdel-Fatah, T. M., Rees, R. C., Pockley, A. G., Moseley, P., Ball, G. R., Chan, S. Y., …Miles, A. K. (2017). The localization of pre mRNA splicing factor PRPF38B is a novel prognostic biomarker that may predict survival benefit of trastuzumab in patients with breast cancer overexpressing HER2. Oncotarget, 8(68), 112245-112257. https://doi.org/10.18632/oncotarget.22496

Cancer biomarkers that can define disease status and provide a prognostic insight are essential for the effective management of patients with breast cancer (BC). The prevalence, clinicopathological and prognostic significance of PRPF38B expression... Read More about The localization of pre mRNA splicing factor PRPF38B is a novel prognostic biomarker that may predict survival benefit of trastuzumab in patients with breast cancer overexpressing HER2.

Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer (2016)
Journal Article
Fusco, N., Geyer, F. C., De Filippo, M. R., Martelotto, L. G., Ng, C. K., Piscuoglio, S., …Weigelt, B. (2016). Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer. Modern Pathology, 29(11), 1292-1305. https://doi.org/10.1038/modpathol.2016.134

Adenoid cystic carcinoma of the breast is a rare histological type of triple-negative breast cancer with an indolent clinical behavior, often driven by the MYB-NFIB fusion gene. Here we sought to define the repertoire of somatic genetic alterations i... Read More about Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer.

Review of the national external quality assessment (EQA) scheme for breast pathology in the UK (2016)
Journal Article
Rakha, E. A., Bennett, R. L., Coleman, D., Pinder, S. E., & Ellis, I. O. (2017). Review of the national external quality assessment (EQA) scheme for breast pathology in the UK. Journal of Clinical Pathology, 70(1), 51-57. https://doi.org/10.1136/jclinpath-2016-203800

Background: The National Health Service Breast Screening Programme (NHSBSP; pathology) external quality assurance (EQA) scheme aims to provide a mechanism for examination and monitoring of concordance of pathology reporting within the UK. This study... Read More about Review of the national external quality assessment (EQA) scheme for breast pathology in the UK.

Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer (2014)
Journal Article
Abdel-Fatah, T. M., Russell, R., Albarakati, N., Maloney, D. J., Dorjsuren, D., Rueda, O. M., …Madhusudan, S. (2014). Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer. Molecular Oncology, 8(7), 1326-1338. https://doi.org/10.1016/j.molonc.2014.04.009

FEN1 has key roles in Okazaki fragment maturation during replication, long patch base excision repair, rescue of stalled replication forks, maintenance of telomere stability and apoptosis. FEN1 may be dysregulated in breast and ovarian cancers and ha... Read More about Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer.